Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
$3.28
$2.33
$60.00
$7.34M1.28212,944 shs56,500 shs
iBio, Inc. stock logo
IBIO
iBio
$0.85
+6.9%
$0.73
$0.56
$6.89
$16.62M0.61.40 million shs5.89 million shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$2.15
+0.9%
$1.10
$0.47
$5.20
$10.94M1.32446,792 shs122,723 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.48
+2.8%
$1.50
$0.94
$2.07
$23.79M0.96242,105 shs254,657 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.00%0.00%0.00%0.00%0.00%
iBio, Inc. stock logo
IBIO
iBio
0.00%+6.72%+7.90%-3.30%-61.03%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-9.75%+129.01%+162.32%+1,047.01%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%-4.00%-14.29%-19.55%-24.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
1.8647 of 5 stars
3.50.00.00.02.50.00.6
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.6899 of 5 stars
0.05.00.00.01.10.00.6
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.7253 of 5 stars
0.05.00.00.02.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.00
N/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00491.72% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FWBI, NNVC, IBIO, and MTNB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/A$6.54 per shareN/A
iBio, Inc. stock logo
IBIO
iBio
$375K44.29N/AN/A$1.41 per share0.60
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
-$15.80MN/A0.00N/AN/AN/A-102.83%-22.74%N/A
iBio, Inc. stock logo
IBIO
iBio
-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.89N/AN/AN/A-123.06%-94.28%N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.40
1.21
1.58
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47

Institutional Ownership

CompanyInstitutional Ownership
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
12.30%
iBio, Inc. stock logo
IBIO
iBio
7.90%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%

Insider Ownership

CompanyInsider Ownership
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
0.49%
iBio, Inc. stock logo
IBIO
iBio
0.58%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
First Wave BioPharma, Inc. stock logo
FWBI
First Wave BioPharma
92.48 million2.46 millionNot Optionable
iBio, Inc. stock logo
IBIO
iBio
10019.66 million9.82 millionN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

First Wave BioPharma stock logo

First Wave BioPharma NASDAQ:FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

iBio stock logo

iBio NYSE:IBIO

$0.85 +0.05 (+6.93%)
Closing price 04:00 PM Eastern
Extended Trading
$1.05 +0.21 (+24.62%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$2.15 +0.02 (+0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 -0.05 (-2.56%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.48 +0.04 (+2.78%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 +0.01 (+0.34%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.